Development of germinoma during the treatment of systemic-onset juvenile idiopathic arthritis with infliximab

Vol.22 No.4

Case Report

Development of germinoma during the treatment of systemic-onset juvenile idiopathic arthritis with infliximab

Authors

Shunichiro Takezaki¹ , Yuka Okura¹ , Mizuho Ichikawa¹ , Daisuke Suzuki¹ , Junjiro Ohshima¹ , Makoto Kaneda¹ , Yuko Cho¹ , Masafumi Yamada¹ , Nobuaki Kawamura¹ , Akihiro Iguchi¹ , Ichiro Kobayashi¹ , Tadashi Ariga¹

Department of Pediatrics, Hokkaido University School of Medicine, North-15 West-7, Kita-ku, Sapporo, 060-8638, Japan

Received:

13 July 2011

Accepted:

24 October 2011

Published online:

10 November 2011

Full Text

PDF　(member's only)

Abstract

We report a 19-year-old patient with systemiconset juvenile idiopathic arthritis (JIA) who developed a mediastinal germinoma during treatment with infliximab. Although the cancer risk of infliximab is controversial, this agent may have accelerated the growth of the germinoma. We conclude that the indications for tumor necrosis factor (TNF) inhibitors should be strictly decided and that a nationwide cohort study is necessary to assess the risk of cancer in patients with JIA exposed to biologics.

Key words

Juvenile idiopathic arthritis - Infliximab - Malignancy - Germinoma